The Carticept Medical and Cartiva family of companies, based in Alpharetta, GA, are developing and marketing next generation medical device solutions for the orthopedics and extremities markets.
Carticept Medical’s flagship product, the Navigator® injection system, is an FDA cleared technology platform that improves the safety, efficiency and accuracy of many common injection procedures.
Cartiva, Inc. develops and markets the Cartiva® Synthetic Cartilage Implant (Cartiva SCI), used to treat focal chondral or osteochondral defects of the articular cartilage surface associated with joint pain or decreased range of motion. Cartiva SCI is a proprietary biomaterial that was designed to mimic the key attributes of natural cartilage. Cartiva has completed enrollment in its pivotal MOTION Trial, a 236-patient randomized controlled trial to determine the safety and effectiveness of Cartiva SCI compared to fusion for the treatment of osteoarthritis of the first metatarsophalangeal joint. The MOTION trial is the largest prospective randomized clinical trial for osteoarthritis of the first MTP joint. Cartiva recently submitted the first module of its PMA application to the FDA and expects to submit the final module, including the clinical data from the MOTION Trial, in the second quarter of 2015.